Redeye: EG7 - Tough comps in a transition year
Redeye updates on EG7 post Q4-results which came in lower than expected, driven mainly by Big Blue Bubble which saw a faster revenue decline than we expected. On the back of this, we have adopted a more cautious view on 2024 while also lowering our 2025-26E forecasts somewhat. Still, we highlight that 2024 will be a transition year ahead of stronger growth in 2025-26E as ongoing growth investments starts to yield revenue.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/